Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
2910 participants
OBSERVATIONAL
2020-04-27
2022-02-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Developement and Evaluation of Serological Assays for COVID-19
NCT04377763
Screening for COVID-19 and Monitoring of Serological Responses to SARS-CoV-2 in Healthcare Workers
NCT04370119
Immune Response to Covid-19 in 300 Health Care Workers With Mild Symptoms
NCT04356586
Sensitivity Evaluation of Serological Tests for Covid-19
NCT04678024
HLA-G Immuno-Inhibitor Checkpoint Study in Patients With COVID-19 Infection: Molecular and Cellular Assessment
NCT04613297
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ETH cohort
employees or students at ETH Zurich, Switzerland
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Between 18 and 64 years of age at the start of the study
* Signed informed consent
Exclusion Criteria
* In quarantine or self-confinement at the start of the study
* Active COVID-19 infection at the start of the study:
* Diagnosed with a laboratory test
* Suspected based on typical symptoms such as fever (\>38°C), acute pulmonary ex-acerbation or sudden loss of gustatory taste
* The following medical condition
* With continuous steroid therapy/ chemotherapy/immunsuppressive therapy
* In treatment for cancer
* With severe autoimmune disease
18 Years
64 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Goldhahn Jörg
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Goldhahn Jörg
Deputy director of the Institute for Translational Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jörg Goldhahn, MD
Role: STUDY_CHAIR
ETH Zurich
Susanne Ulbrich, Prof. Dr.
Role: STUDY_DIRECTOR
ETH Zurich
Markus Stoffel, Prof. Dr.
Role: STUDY_DIRECTOR
ETH Zurich
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ETH
Zurich, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20-05
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.